Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035531 | 0.86 | FEN1 (0.40) | BTKPIK3CAMTORBRAF | |
| SCHEMBL22200738 | 0.85 | BTK (0.40) | BTKPIK3CAMTORERN1BRAF | |
| SCHEMBL25035635 | 0.85 | BTK (0.38) | BTKPIK3CAMTORERN1BRAF | |
| SCHEMBL25034212 | 0.84 | RXFP1 (0.41) | PIK3CAMTORHSD11B1 | |
| SCHEMBL25035541 | 0.83 | EGFR (0.42) | PIK3CAMTOR | |
| SCHEMBL25035654 | 0.81 | PIK3CA (0.36) | BTKPIK3CAMTOR | |
| SCHEMBL22191431 | 0.81 | ERN1 (0.62) | ERN1 | |
| SCHEMBL22191432 | 0.81 | ERN1 (0.62) | ERN1 | |
| SCHEMBL25034103 | 0.79 | PIK3CA (0.48) | PIK3CAMTORPOLB | |
| SCHEMBL22200739 | 0.78 | BTK (0.43) | BTKPIK3CAMTORBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BTK 1775/4885PIK3CA 211/4885MTOR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.